Compare Stocks
Healthcare Global Enterprises announced Q1FY23 Result :
- Overall ARPOB stood at Rs. 38,454 vs. Rs. 36,316 in Q1 FY22, a growth of 5.9%
- Overall AOR stood at 64.6% vs. 57.8% in Q1 FY22, a rise of 680 basis points
- EXISTING CENTERS:
- ARPOB stood at Rs. 40,606 vs. Rs. 35,979 in Q1 FY22, a growth of 12.9%
- AOR stood at 64.0% vs. 59.4% in Q1 FY22, a rise of 460 basis points
- RoCE stood at 19.0% vs. 15.4% in FY22, a rise of 360 basis points
- NEW CENTERS:
- ARPOB stood at Rs. 32,968 vs. Rs. 32,295 in Q1 FY22, a growth of 2.1%
- AOR stood at 66.1% vs. 53.5% in Q1 FY22, a rise of 1,260 basis points
- RoCE stood at -4.6% vs. -8.3% in FY22
Commenting on the results, Dr. B.S. Ajaikumar, Executive Chairman, HealthCare Global Enterprises Ltd. said, HCG is a leading Oncology care provider, which is patient centric, technology-oriented and outcome based. Our focus has been on Oncology in conjunction with local partners in some areas, which has built a strong legacy as a World-class Oncology Institution and a go-to brand for oncological treatment & services across India. Our focus on strong clinical talent, good infrastructure, technology, and timely upgradation of the same has enhanced or ability to deliver exceptional clinical outcomes equal to or better than global standards. And in the very near future, we are putting together the data on Head & Neck and Breast Cancer on these outcomes. HCG today is not only a service provider but has taken a lead role in Research and Academics. Recently, we have acquired Next Generation Sequencer and in the process of acquiring circulating tumour cells (CTC platform). These additions are already enhancing our capabilities in precision diagnosis leading to early detection of recurrent tumours and genomic guided therapy. We have a separate tumour board for this with relevant expertise. In addition, we have introduced Enterprise RIS PACS, in collaboration with Siemens for the first time in the country for AI based precision imaging which will enhance our research capabilities. Further, HCG is introducing first of its kind in the country, AI enabled Adoptive Radiotherapy in our Centre of Excellence which will provide precision radiation oncology.
Mr. Raj Gore, CEO HealthCare Global Enterprises Ltd. added, We are happy to report robust growth for quarter ended June 2022. Our consolidated revenues for Q1FY23 grew by 26% on YoY basis and we have reported PBT of Rs. 10 crs for Q1FY23 as compared to loss of Rs. 9 crs in Q1FY22. We are also happy to report that we have been able to successfully accelerate the financial performance for HCG over the last 8 quarters. Our revenues have increased by ~1.7x since Q2FY21 on a quarterly run rate basis. Correspondingly our EBIDTA in absolute terms have grown by 2.4x times over the last eight quarters and have been able to achieve consecutive PBT positive quarter. We have been working on multiple fronts to take HCG to greater heights by constantly improving holistic value that we offer to our patients and thus create value for the business in a sustainable manner. Four key areas of our strategic roadmap that we are currently working on are: 1) Digital transformation, 2) Cost optimization and efficiency enhancement, 3) Growth of Medical Value Travel, 4) Inorganic acquisitions. We are confident of maintaining our growth momentum going forward.
